Background Immune checkpoint inhibitors (ICIs) have led to dramatic improvements in
survival a subset of patients with non-small cell lung cancer (NSCLC); however, they have …

Abstract Background: Immune checkpoint inhibitors (ICIs) can lead to one of the common
and quite serious immune-related adverse events (irAEs) in a real-world setting, namely …

Objectives: Chronic obstructive pulmonary disease (COPD) is the most common co-
morbidity associated with non-small cell lung cancer (NSCLC) patients. Immune checkpoint …

Background Immune checkpoint inhibitors (ICIs) are standard treatments for advanced non-
small cell lung cancer and have expanded use in small cell lung cancer. Although generally …

Background Immune checkpoint inhibitors (ICIs) have improved survival and are
increasingly used for non-small cell lung cancer. However, use may be limited by immune …

Abstract Objectives Immune checkpoint inhibitors (ICIs) can cause pneumonitis in lung
cancer patients. We aimed to identify the clinical and radiologic characteristics, incidence …

Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for non-small
cell lung cancer (NSCLC). However, along with demonstrating remarkable efficacy, ICIs can …

Background Immune checkpoint inhibitors (ICIs) have become standard treatments for lung
cancer patients. Immune checkpoint inhibitor-related pneumonitis (CIP) was the leading …

Background The treatment efficacy of immune checkpoint inhibitor (ICI) and clinical
outcomes in patients with non‐small cell lung cancer (NSCLC) who develop severe grade …

Immune checkpoint inhibitors (ICIs) have shown definite therapeutic effects in various types
of cancers, especially non-small cell lung cancer (NSCLC). However, ICIs have unique side …